LivaNova PLC (NASDAQ:LIVN) Shares Sold by Jane Street Group LLC

Jane Street Group LLC lowered its position in shares of LivaNova PLC (NASDAQ:LIVN) by 12.8% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 133,213 shares of the company’s stock after selling 19,525 shares during the period. Jane Street Group LLC owned 0.25% of LivaNova worth $6,999,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of the business. Arizona State Retirement System boosted its position in shares of LivaNova by 2.0% during the 2nd quarter. Arizona State Retirement System now owns 15,104 shares of the company’s stock worth $828,000 after acquiring an additional 299 shares in the last quarter. Atria Investments Inc lifted its position in LivaNova by 6.2% in the third quarter. Atria Investments Inc now owns 5,653 shares of the company’s stock valued at $297,000 after acquiring an additional 331 shares during the last quarter. Fifth Third Bancorp boosted its stake in LivaNova by 97.1% in the second quarter. Fifth Third Bancorp now owns 674 shares of the company’s stock valued at $37,000 after acquiring an additional 332 shares in the last quarter. State of Alaska Department of Revenue grew its holdings in shares of LivaNova by 7.3% during the third quarter. State of Alaska Department of Revenue now owns 6,246 shares of the company’s stock worth $328,000 after purchasing an additional 425 shares during the last quarter. Finally, Rhumbline Advisers increased its position in shares of LivaNova by 0.4% during the second quarter. Rhumbline Advisers now owns 183,132 shares of the company’s stock worth $10,039,000 after purchasing an additional 659 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Wall Street Analysts Forecast Growth

LIVN has been the topic of a number of research reports. Mizuho dropped their price target on LivaNova from $80.00 to $70.00 and set an “outperform” rating on the stock in a research note on Thursday, October 31st. The Goldman Sachs Group started coverage on shares of LivaNova in a report on Friday, October 4th. They issued a “buy” rating and a $65.00 target price on the stock. Robert W. Baird raised their price objective on shares of LivaNova from $66.00 to $72.00 and gave the stock an “outperform” rating in a research report on Thursday, October 31st. Baird R W raised shares of LivaNova from a “hold” rating to a “strong-buy” rating in a report on Tuesday, September 17th. Finally, StockNews.com cut LivaNova from a “strong-buy” rating to a “buy” rating in a research report on Saturday, November 16th. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $69.17.

Insiders Place Their Bets

In other news, Director Francesco Bianchi sold 1,250 shares of the company’s stock in a transaction on Wednesday, December 11th. The shares were sold at an average price of $50.99, for a total transaction of $63,737.50. Following the transaction, the director now directly owns 7,522 shares of the company’s stock, valued at $383,546.78. This represents a 14.25 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.27% of the stock is currently owned by insiders.

LivaNova Trading Down 1.2 %

Shares of LivaNova stock opened at $51.50 on Friday. The company has a quick ratio of 2.87, a current ratio of 3.37 and a debt-to-equity ratio of 0.46. The firm has a market cap of $2.80 billion, a price-to-earnings ratio of 122.62 and a beta of 0.98. LivaNova PLC has a 52-week low of $43.15 and a 52-week high of $64.47. The company’s 50-day simple moving average is $51.97 and its 200-day simple moving average is $51.49.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.